In two placebo-controlled trials (2676 current/former smokers with COPD and frequent exacerbations), astegolimab every 2 weeks lowered exacerbation rates in ALIENTO (RR 0·85, p=0·049) but not significantly in ARNASA (RR 0·85, p=0·068); 4-weekly: RR 0·93 and 0·82.
RCTn = 2,676
Papi et al. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials